Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that bilateral orchiectomy allows most transgender women to stop anti-androgen medications, with 91.7% discontinuing them post-surgery and 25% reducing estrogen use.

This case report describes a Canadian Husky dog with sertolioma that exhibited dermatological symptoms and aggressive behavior, both of which improved significantly after surgery.

This case study highlights the late diagnosis of complete androgen insensitivity syndrome in a 31-year-old woman, emphasizing the psychological impact and need for individualized treatment guidelines.

A man developed hair loss from testosterone treatment but improved with additional medication.

In this case report, a patient with pseudovaginal perineoscrotal hypospadias due to 5α-reductase deficiency presented gender dysphoria, and after genomic sequencing confirmation, injectable testosterone undecanoate treatment successfully developed desired male secondary sexual characteristics.

In this study, the authors reported a case of alopecia X in a German Spitz dog and found that treatment with orchiectomy and melatonin resulted in partial hair regrowth and improved the dog's dermatological condition.

In this reported case, a male German Spitz diagnosed with alopecia X showed partial regrowth of alopecic areas after treatment with orchiectomy and melatonin, indicating this combination's potential effectiveness for the condition.

This study highlights the need for a comprehensive andrological assessment at diagnosis, including semen and hormonal analysis, to guide fertility preservation strategies, and found that post-orchidectomy semen samples showed improved DNA integrity for assisted reproductive technologies.

In this case study, a 2-year-old Pomeranian dog from Mizoram, India, with alopecia X showed significant hair growth and improved skin condition after undergoing neutering and receiving omega-3 and omega-6 fatty acid supplements.

This paper reports a case of sebaceous carcinoma developing at the site of chronic candidiasis in a patient with keratitis–ichthyosis–deafness syndrome, without presenting new generalizable findings.

Hair loss in women is genetic, diagnosed by examination and biopsy, and treated with minoxidil, finasteride, or transplantation.

This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.

In this study, combining flutamide with finasteride showed additive effects in reducing tumor and prostate growth in a mouse model predictive of androgen-sensitive prostate cancer.

Hormone treatment caused hair loss, finasteride helped regrowth.

Finasteride use may be linked to rare testicular tumor, but more research needed.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

This study found that blocking androgen receptors inhibits testicular descent in rats more effectively during the early stages of gubernacular outgrowth than inhibiting 5a-reductase.

This study found that finasteride impaired stress reactivity and reduced exploratory and impulsive behaviors in rats, potentially by altering the hypothalamus-pituitary-adrenal axis function.

This review discusses gender identity disorder in Japan, highlighting the high prevalence and challenges in accessing appropriate treatment, and calls for wider understanding among medical professionals.

Panitumumab can cause excessive ear hair growth.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This review discusses 46,XY disorders of sex development caused by defects in androgen production and highlights the need for long-term care from experienced multidisciplinary teams, but it reports no new clinical findings.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.

This study emphasizes the necessity of confirming elevated testosterone levels detected by immunoassay with liquid chromatography-tandem mass spectroscopy before pursuing more complex diagnostic evaluations.

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.

This review discusses sex-based differences in immune responses, focusing on genetic, hormonal, and microbiome factors influencing infections like COVID-19, and reports no clinical results.

This article reviews the care of transgender patients, encompassing diagnosis, treatment options, and challenges in health care access, but does not present new research findings; the authors emphasize the critical role of providers in addressing transgender health needs.

This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.